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Summary
 
For T cells to become functionally activated they require at least two signals. The B7 costimu-
latory molecules B7-1 and B7-2 provide the “second signal” pivotal for T cell activation. In
this report, we studied the relative roles of B7-1 and B7-2 molecules in the induction of anti-
tumor immunity to the T cell thymoma, EL4. We generated EL4 tumor cells that expressed
B7-1, B7-2, and B7-1
 
1
 
B7-2 by transfecting murine cDNAs. Our results demonstrate that
EL4–B7-1 cells are completely rejected in syngeneic mice. Unlike EL4–B7-1 cells, we find that
EL4–B7-2 cells are not rejected but progressively grow in the mice. A B7-1– and B7-2–EL4
double transfectant was generated by introducing B7-2 cDNA into the EL4–B7-1 tumor line
that regressed in vivo. The EL4–B7-1
 
1
 
B7-2 double transfectant was not rejected when im-
planted into syngeneic mice but progressively grew to produce tumors. The double transfec-
tant EL4 cells could costimulate T cell proliferation that could be blocked by anti–B7-1 anti-
bodies, anti–B7-2 antibodies, or hCTLA4 immunoglobulin, showing that the B7-1 and B7-2
molecules expressed on the EL4 cells were functional. In vivo, treatment of mice implanted
with double-transfected EL4 cells with anti–B7-2 monoclonal antibody resulted in tumor re-
jection. Furthermore, the EL4–B7-2 and EL4–B7-1
 
1
 
B7-2 cells, but not the wild-type EL4
cells, were rejected in interleukin 4 (IL-4) knockout mice. Our data suggests that B7-2 ex-
pressed on some T cell tumors inhibits development of antitumor immunity, and IL-4 appears to
play a critical role in abrogation of the antitumor immune response.
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T
 
he activation of T lymphocytes for optimal prolifera-
tion and induction of effector functions requires at
least two distinct signals (1). The antigen-specific “first sig-
nal” is delivered by the engagement of the T cell antigen
receptor with the peptide–MHC on APCs. The “second
signal,” or costimulatory signal, is antigen independent and
provided by soluble factors, such as IL-2, or through a set
of surface molecules expressed on professional APCs (2). T
cell antigen receptor signaling by antigen without proper
costimulation may induce a state of antigen-specific unre-
sponsiveness termed anergy (3). Of the known costimula-
tory molecules expressed on APCs, the B7 family delivers
the most potent costimulatory signal. Two B7 molecules
have been identified: B7-1 (CD80; 4) and B7-2 (CD86; 5,
6), both belonging to the Ig gene superfamily (7). Although
these two proteins share the ability to costimulate T cells
through CD28, they show only 25% identity to each other
(6, 8). Both B7-1 and B7-2 are usually found on APCs
such as dendritic cells and B lymphocytes and can also be
expressed on T cells. They often show differences in tem-
poral expression after activation, with B7-2 appearing first
and B7-1 later (9, 10). The B7 molecules interact with
CD28 and CTLA4 receptors that are expressed on T cells.
Studies with CTLA4–Ig, a soluble fusion protein of the ex-
tracellular domain of CTLA4 and the Fc portion of an
IgG1 molecule, indicate that both B7 family members bind
to CTLA4 with a 20–200-fold greater affinity than to
CD28 (11, 12). CD28 is the most important costimulatory
receptor constitutively expressed on the surface of T cells.
Ligation of CD28 by B7-1 or B7-2 results in T cell acti-
vation and induction of effector function (13). CTLA4
shows a 31% identity in amino acid sequence to CD28 and
appears on the cell surface after B7 engages CD28 (14). In
contrast to CD28, CTLA4 appears to be a negative regula-
tor of T cell activation (15), indicating that the B7 pathway
may also negatively affect T cell responses (16).
The majority of tumor cells are of low immunogenicity
and generally lack expression of costimulatory molecules 
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(17). According to the two-signal hypothesis of T cell activa-
tion, absence of B7-CD28 interaction would result in T cell
anergy due to the lack of costimulation. This leads to the
idea that if tumor cells could be made to express costimula-
tory molecules, they would become better APCs and gener-
ate tumor-specific CTLs, promoting tumor regression. By
transfection of the murine B7-1 gene into different tumor
cells, protective and sometimes curative immunity against
wild-type tumors has been induced in several mouse models
(17, 18). The protective effects appear to vary depending on
the tumor system studied. In particular, the immunogenicity
of the tumor is one of the factors that determines the success
of B7-1–mediated tumor regression (19).
Since B7-2 was discovered, the effects of B7-2 on the
induction of antitumor immunity have been studied and
compared with those of B7-1. More recently, B7-2 has
been transfected into a number of tumor cell lines with dif-
fering results. Although B7-2 expression on the tumor cell
surface induces rejection of BSC-1 (20) and P815 masto-
cytoma cells (21), it was found to be ineffective with EL4
thymoma cells (22) and MCA 102 fibrosarcoma cells (21).
Matulonis et al. have reported that B7-1 is superior to B7-2
in its capacity to provide protection to wild-type leukemia
cell challenge and in its ability to regress existing tumors
(23). Gajewski has also reported that B7-1–, but not B7-2–
transfected P815 cells, were able to generate alloantigen-
specific CTL activity and to costimulate proliferation of
CD8
 
1
 
 lymphocytes in the presence of low doses of anti-
CD3 mAb (24).
We have investigated the roles of B7-1 and B7-2 on the
immune system utilizing B7-1– and B7-2–transfected (B7-1–
EL4 and B7-2–EL4) and B7-1
 
1
 
B7-2 double–transfected
EL4 (B7-1
 
1
 
B7-2–EL4) cells in an in vivo tumor model. In
this report, we describe the role of B7 costimulatory mole-
cules B7-1 and B7-2 in the induction of the antitumor re-
sponse. We have previously demonstrated that EL4–B7-1
cells are rejected in syngeneic C57BL/6 mice and that
EL4–B7-2 cells produce tumors that grow as well as the
wild-type EL4 (EL4-wt)
 
1
 
 tumors (22). In this report, we
show that B7-1
 
1
 
B7-2 double-transfected EL4 cells were
not rejected but progressively grew to produce tumors.
Our data suggests that the effects of B7-2 are dominant in
that, when expressed on EL4 tumors along with B7-1, B7-2
inhibits the development of antitumor immunity. Suppres-
sion of the antitumor immune response by B7-2 on the
EL4 cells was IL-4–dependent because IL-4–deficient mice
rejected B7-2–expressing EL4 cells.
 
Materials and Methods
 
Mice.
 
Female C57BL/6 mice 6–8 wk of age were purchased
from Harlan Sprague Dawley, Inc. Female C57BL/6 (nu/nu)
mice were purchased from Taconic Farms, Inc. IL-4 and IL-10
gene–disrupted C57BL/6 mice were purchased from The Jack-
son Laboratory. The mice were maintained in accordance with
the guidelines of the Committee on Animals of Harvard Medical
School and the Committee on Care and Use of Laboratory Ani-
mals of the Institute of Laboratory Animal Resources, National
Research Council, as stated in the Department of Health and
Human Services publication 85-23 (revised 1985).
 
Cell Lines.
 
The tumor cell lines used in this study were ob-
tained from the American Type Culture Collection (ATCC).
The carcinogen-induced lymphoma EL4 is of C57BL/6 (H-2
 
b
 
)
origin. The EL4–B7-1 cells were provided by Dr. James Allison
(University of California, Berkeley, CA). EL4–B7-2 cells were
generated by introducing murine B7-2 cDNA into a pCDM8
vector by electroporation into EL4-wt cells (ATCC) as described
(22). The transfectants were selected in the presence of 1 mg/ml
G418 (Life Technologies). In another series, EL4–B7-1 cells (ob-
tained from Dr. James Allison) were transfected with murine B7-2
cDNA to produce EL4–B7-1
 
1
 
B7-2 as described above. These
transfectants were selected in 800 
 
m
 
g/ml hygromycin B (Boeh-
ringer Mannheim). The mock transfectant EL4 line (EL4-neo/
hygro) was derived similarly but transfected only with the genes for
the selection antibiotics (G418 and hygromycin B). After 3–4 wk,
cells growing in the presence of the drugs were sorted for B7-2–
expressing cells with anti–mB7-2 mAb (GL1) using a Becton
Dickinson FACS Vantage
 
TM
 
 cell sorter. The B7-2–expressing
cells were then subcloned and clones showing stable B7-2 ex-
pression were used in the experiments. The clones were screened
for B7 expression once per week. All cell lines were maintained
at 37
 
8
 
C in 10% CO
 
2
 
 in DMEM (Life Technologies) containing
10% FCS (Fetalclone I; Hyclone), 1 mg/ml G418 (Life Technol-
ogies), and/or 800 
 
m
 
g/ml hygromycin B (Boehringer Mann-
heim).
 
Antibodies.
 
Anti–B7-1 antibody (1G10) was provided by Dr.
Nasrin Nabavi (Hoffmann-LaRoche Research Center, Nutley,
NJ; 28). Anti–B7-2 antibody (GL1) was obtained from the GL1
hybridoma line (ATCC). The antibodies were purified from as-
citic fluid on protein G columns (LKB/Pharmacia). The anti–B7-1
and anti–B7-2 antibodies are both of rat IgG2a isotype. The anti-
murine CD3 hybridoma line 145-2C11 was provided by Dr. Jef-
frey Bluestone (Ben May Institute, University of Chicago, Chi-
cago, IL). Human CTLA4–Ig was provided by Dr. Peter Linsley
(Bristol Myers Squibb, Seattle, WA).
 
Flow Cytometry.
 
Spleen cells and tumor cells from mice or
those growing in culture were harvested and washed three times
with cold 1% BSA/PBS, pH 7.2, and then incubated with either
supernatant from antibody-producing hybridomas or purified an-
tibody (5 
 
m
 
g/ml) diluted in 1% BSA/PBS for 30 min at 4
 
8
 
C. The
cells were then washed two to three times with the 1% BSA/PBS
solution before incubating with FITC- or PE-conjugated goat
anti–mouse Ig, goat anti–rat Ig, or goat anti–human Ig secondary
antibodies (Zymed). The secondary antibodies were diluted 1/50
in 1% BSA/PBS and then incubated with the cells for 30 min at
4
 
8
 
C in the dark. After this incubation, the cells were washed
three times with PBS and then fixed with an equal volume of 1%
paraformaldehyde/PBS solution. Analysis was performed using a
FACScan
 
TM
 
 (Becton Dickinson). FITC- and PE-conjugated anti-
bodies used for direct staining were obtained from PharMingen
and included the following: anti–B7-1–FITC (clone 16.10A1),
anti–B7-2–PE (clone GL1), and anti-CD95L–PE (clone KAY-10).
For binding studies with hCTLA4–Ig, PE-conjugated goat
F(ab
 
9
 
)
 
2
 
 anti–human IgG (Southern Biotechnology, Inc.) was used
for indirect staining.
 
Costimulation Assay.
 
T lymphocytes freshly isolated from
C57BL/6 mouse spleen cells were positively selected using Micro-
Beads bound with anti-Thy1.2 (CD90) on an appropriate col-
umn (MACS; Miltenyi Biotec). This purification method yielded
 
1
 
Abbreviation used in this paper:
 
 wt, wild-type. 
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95% enriched T cells. The positively selected T lymphocytes
were used in costimulation assays as responder cells at a concen-
tration of 10
 
5
 
 cells/50 
 
m
 
l/well of 96-well tissue culture plates
(Costar Corp.). Untransfected and transfected EL4 cells were
treated overnight with 40 
 
m
 
g/ml mitomycin C (Sigma Chemical
Co.) and then washed thoroughly and added as stimulator cells at
10
 
5
 
 cells/25 
 
m
 
l/well. Supernatant from anti-CD3–secreting hy-
bridoma 145-2C11 cultures was added at 1/100 final dilution/
100 
 
m
 
l/well. In some experiments, anti–B7-1 antibody, anti–B7-2
antibody, or hCTLA4–Ig was added at a final concentration of
2 
 
m
 
g/ml per 100 
 
m
 
l/well for blocking in vitro costimulation. The
plates were then incubated at 37
 
8
 
C in a humidified CO
 
2
 
 incuba-
tor for 48 h. The plates were then pulsed with 1 
 
m
 
Ci of 
 
3
 
H-TdR
per well for 16 h and harvested using a Tomec Mach II 96 cell
harvester and counted on a 1205 Betaplate liquid scintillation
counter (Wallac, Inc.).
 
Generation of T Cell Lines.
 
To generate long-term T cell lines
specific for each of the EL4 tumor cells, spleen cells (0.5–1 
 
3
 
10
 
6
 
/well) from mice implanted with each of the tumors were re-
moved on days 10 to 12 and stimulated with the corresponding
mitomycin C–fixed (40 
 
m
 
g/ml overnight) EL4 cells (EL4–B7-1,
EL4–B7-2, or EL4–B7-1
 
1
 
B7-2 cells; 2 
 
3
 
 10
 
5
 
 cells/well) to-
gether with gamma-irradiated (5,000 rads) syngeneic spleen cells.
The T cells were restimulated every 12–14 d with the corre-
sponding mitomycin C–treated tumor cells that had been used to
stimulate them in vivo, resulting in the generation of long-term
T cell lines. The T cell lines were grown in DMEM supple-
mented with sodium pyruvate, 
 
l
 
-glutamine, penicillin, strepto-
mycin, gentamycin sulfate, nonessential amino acids (0.1 mM),
MEM vitamin mixture (1
 
3
 
; BioWhittaker), asparagine (0.1 mM),
folic acid (0.1 mg/ml), 2-ME (5 
 
3
 
 10
 
2
 
5
 
 M; Sigma Chemical
Co.), 10% FBS (Hyclone), and 2% T cell growth factor (T-STIM;
Collaborative Biomedical Products). The T cell lines thus gener-
ated were tested for cytotoxicity, cytokine production, and in
vivo functional effects on tumor growth.
 
51
 
Cr Release Assay to Test Cytolytic Activity.
 
Effector cells were
harvested, washed, and adjusted to 10
 
6
 
 cells/ml, and varying
numbers of effector cells (Ficoll-purified if necessary) were added
to 5 
 
3
 
 10
 
3
 
 
 
51
 
Cr-labeled target cells in 150 
 
m
 
l of culture medium
in 96-well v-bottomed plates. After a 4-h incubation, 50 
 
m
 
l cul-
ture supernatant was collected and measured in a gamma counter.
The mean percentage specific lysis of triplicate wells was calculated
as follows: % specific lysis 
 
5
 
 ([cpm experimental release 
 
2
 
 cpm
spontaneous release]/[cpm maximum release 
 
2
 
 cpm spontaneous
release]) 
 
3
 
 100. The spontaneous release of the 
 
51
 
Cr-labeled tar-
get cells was 
 
,
 
20% in all experiments.
 
In Vitro Cytokine Assay.
 
Supernatants were collected from T
cells 40 h after activation in vitro with the corresponding EL4 cell
line in the presence of syngenic spleen cells as APCs (see described
generation of T cell lines). The concentrations of IL-2, IL-4, IL-10,
IFN-
 
g
 
, and TNF-
 
a
 
 were measured by quantitative capture ELISA
according to the guidelines of the manufacturers (PharMingen).
In brief, purified rat mAb to mouse IL-2 (clone JES6-1A12), IL-4
(clone BVD4-1D11), IL-10 (clone JES5-2A5), IFN-
 
g
 
 (clone
R4-6A2), and TNF-
 
a
 
 (clone MP6-XT22) were obtained from
PharMingen and used to coat ELISA plates (Immulon 4; Dyna-
tech Laboratories, Inc.). Recombinant mouse cytokines (IL-2, IL-4,
IL-10, IFN-
 
g
 
, and TNF-
 
a
 
; PharMingen) were used to construct
standard curves, and biotinylated rat mAb to mouse IL-2 (clone
JES6-5H4), IL-4 (clone BVD4-24G2), IL-10 (clone SXC-1), and
IFN-
 
g
 
 (clone XMG1.2; all PharMingen) were used as the second
Ab. Detection of TNF-
 
a
 
 was performed with biotinylated poly-
clonal rabbit IgG (PharMingen). Plates were developed with
 
TMB microwell peroxidase substrate (Kirkegaard & Perry Labo-
ratories, Inc.) and read after the addition of stop solution at 450
nm using a microplate reader (model 3550; Bio-Rad Laborato-
ries).
 
Animal Studies.
 
C57BL/6 syngeneic mice were prepared for
intradermal EL4 cell implantation by shaving their hind flank re-
gions followed by depiliation with Nair (Carter Wallace, Inc.) 24 h
before intradermal implantation of tumor cells. EL4-wt and
transfected EL4 tumor cells were harvested in log phase growth
from tissue culture flasks and washed four times with PBS (Bio-
Whittaker) and resuspended at 4 
 
3
 
 10
 
7
 
 cells/ml in PBS for im-
plantation. Each intradermal injection consisted of 2 
 
3
 
 10
 
6
 
 cells
in 50 
 
m
 
l PBS and was performed using a 1-ml syringe fitted
with a 27-gauge needle. 5–7 d after implantation, a tumor could
be observed at the implantation site. The mice were scored for
tumor growth three times per week and tumor size was docu-
mented by direct measurement in three perpendicular directions
using a Max-Cal caliper (Cole Parmer Instrument Co.) and a
plastic ruler. The experiments were terminated when the tumors
reached 20–22 mm in diameter, if severe ulceration and bleeding
had developed, or the mice had died. The measurements were
recorded as tumor volumes (mm
 
3
 
) from groups of five mice each.
For blocking of the B7 pathway in vivo, mice were injected with
2 
 
3
 
 10
 
6
 
 EL4–B7-1
 
1
 
B7-2 cells that had been premixed with 50 
 
m
 
g
of murine anti–B7-1 or anti–B7-2 antibodies for 10 min at 4
 
8
 
C.
Mice were treated with anti-B7 antibody every other day for 20 d
by i.p. injection at 150 
 
m
 
g/mouse following tumor implantation.
Tumor growth was measured every other day.
 
Adoptive Transfer of Spleen Cells and T Cells.
 
To test the bio-
logical effects of the T cells on tumor growth, a T cell line gener-
ated from EL4–B7-1
 
1
 
B7-2–bearing mice (5 
 
3
 
 10
 
6
 
/mouse) were
intravenously injected into EL4–B7-1–bearing mice 24 h after
tumor implantation. To test the direct effect of the unmanipu-
lated spleen cells from mice (4 
 
3
 
 10
 
6
 
 cells/mouse) that were
bearing EL4–B7-2 tumors for 12 d, spleen cells from these mice
were also intravenously injected into EL4–B7-1–bearing mice
24 h after tumor implantation. The control group received either
PBS or 4 
 
3
 
 10
 
6
 
 spleen cells from normal C57BL/6 mice intrave-
nously.
 
Results
 
Expression of Murine B7 Molecules on EL4 Tumor Cell
Lines.
 
The wild-type tumor, the vector-only–transfected
EL4, EL4–B7-1, and EL4–B7-2, and the double transfec-
tant EL4–B7-1
 
1
 
B7-2 were screened for surface expression
of B7-1, B7-2, and CD95L. B7-1
 
1
 
B7-2 double transfec-
tants were generated by retransfection of EL4–B7-1 cells
with B7-2 cDNA. Cell surface expression was determined
by flow cytometry after indirect immunofluorescent stain-
ing using specific mAbs to B7-1 (16.10A1), B7-2 (GL1), or
the soluble ligand hCTLA4–Ig, which binds to both B7-1
and B7-2. Only clones showing stable expression of B7
molecules were selected for further experimentation. The
EL4-wt cells and the vector neo/hygro–transfected EL4
cells did not show any detectable expression of B7-1 or
B7-2 (Fig. 1 A). EL4–B7-1 cells showed a strong expres-
sion level for B7-1 but no detectable B7-2, as demonstrated
by binding of anti–B7-1 and CTLA4–Ig but not anti–B7-2
(Fig. 1 B). B7-2–transfected EL4 cells stained brightly with
anti–B7-2 antibodies and CTLA4–Ig but not with anti– 
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B7-1 antibody (Fig. 1 B). The double-transfected EL4 cells
showed a fairly equivalent expression for both B7-1 and
B7-2 when compared to the expression levels found on the
single transfectants (Fig. 1 C). None of the cells expressed
CD95L (data not shown).
 
B7-1
 
1
 
B7-2 Double Transfectants Induce Tumors In Vivo.
 
The tumor growth potential of EL4 cells was assessed by
intradermal implantation of 2 
 
3
 
 10
 
6
 
 cells into syngeneic
C57BL/6 mice. EL4-wt cells showed aggressive tumor
growth, producing visible tumors in the mice after only
5–9 d. No significant differences were observed between tu-
mors produced from vector-only–transfected cells (EL4-neo/
hygro) and EL4-wt cells (data not shown), demonstrating
that the transfection process and vector did not have any
effect on the ability of EL4 cells to produce tumors in syn-
geneic mice (data not shown). In the same experiment, the
tumorigenicity of transfected EL4–B7-1, EL4–B7-2, and
double-transfected EL4–B7-1
 
1
 
B7-2 cells were tested by
implanting 2 
 
3
 
 10
 
6
 
 cells into syngeneic C57BL/6 mice.
B7-1–transfected EL4 cells completely regressed by 13–16 d
after implantation (Fig. 2 A). In contrast, the EL4–B7-2
cells continued to grow at a rate similar to that of the EL4-wt
cells. The most aggressive tumor growth was observed with
the double-transfected EL4–B7-1
 
1
 
B7-2 cells, which reached
experimental limits between days 13 and 17, 5–6 d earlier
than the EL4-wt control group (Fig. 2 A). Cumulative data
from all the experiments is presented in Table I. The major-
ity of EL4–B7-1 tumors were rejected, whereas the B7-2–
transfected and B7–1
 
1
 
B7-2 double-transfected EL4 cells
were not rejected by syngeneic mice. Furthermore, the dif-
ference between EL4–B7-1 and EL4–B7-2 or EL4–B7-11
B7-2 in the incidence of tumor rejection and tumor vol-
ume was highly significant (P , 0.0001). In nude mice, all
of the EL4 cell lines (wild type and transfected) showed
similar tumor growth rates (Fig. 2 B). Therefore, the re-
gression of EL4–B7-1 tumors was not due to different rates
of growth of the transfected tumor cells but required the
presence of T cells for the regression to occur.
Expression of B7-1 and B7-2 on EL4 Cells Is Stable In Vivo.
One of our major concerns in these experiments was
whether the expression level of B7 molecules on the sur-
faces of the transfected cells was maintained in vivo for the
complete term of the experiment or whether the cells lost
or lowered their B7 surface expression. If the B7 expression
of the transfectant was to decrease, it could result in an in-
creased growth rate of the tumors in vivo. Progressively
growing tumors from the syngeneic C57BL/6 mice were
removed (explanted) after 20 d, made into single-cell sus-
pensions, and analyzed by flow cytometry to determine
their surface expression levels of B7. Mice implanted with
Figure 1. Expression of B7 mole-
cules on transfected tumor cell lines.
EL4-wt and EL4-neo/hygro (A),
B7-1– and B7-2–single-transfected
cells (B), and B7-1–B7-2–double-
transfected cells (C) from in vitro
were stained with direct PE- or
FITC-conjugated mAbs specific for
a B7-1 (16.10A1) or a B7-2 (GL1)
and with hCTLA4–Ig (followed by
a secondary PE-conjugated goat
anti–human antibody). Ig controls
included staining with normal rat
Ig, hamster Ig, goat Ig, and human
Ig, of which a representative histo-
gram was selected to show the neg-
ative staining. A total of 10,000 cells
were analyzed per sample by flow
cytometry.923 Stremmel et al.
EL4–B7-1 cells did not have tumors available to explant
due to complete tumor regression. The explanted tumor
cells were then stained for B7 expression immediately after
explantation and also after 4 d in tissue culture (Fig. 3). The
explanted EL4–B7-2 cells showed the same expression as
before implantation, and expression was stable when the
cells were maintained in cell culture (Fig. 3). The explanted
EL4–B7-11B7-2 cells also showed stability for the expres-
sion of both B7 molecules on its surface (Fig. 3). The B7-1
expression level of the double-transfected tumor cells was
the same as before implantation. This clearly demonstrates
that, although the EL4–B7-11B7-2 cells still expressed
B7-1 on their surfaces, B7-1 was no longer able to induce
regression and tumor growth killed the mouse.
B7-2 Molecules on the B7-1 and B7-2 Double Transfectants
Are Functional and Costimulate T Cell Responses In Vitro.
To determine the mechanisms for the different immune re-
sponses to EL4–B7-1 and B7-2 tumors, we tested the
transfectants for their ability to costimulate T cell prolifera-
tion. We have previously reported that, although EL4–B7-1
costimulates T cell proliferation, EL4–B7-2 does not co-
stimulate an anti-CD3–induced T cell response. In this se-
ries of experiments, single- and double-transfected EL4 cells
were used as costimulators in a proliferation assay using sub-
mitogenic concentrations of soluble anti-CD3 antibody.
The data presented in Fig. 4 confirmed that EL4–B7-1 cells
costimulated significant amounts of T lymphocyte prolifera-
tion. This proliferation was almost completely blocked by the
addition of anti–B7-1 antibodies or hCTLA4–Ig but was
unaffected by the addition of anti–B7-2 antibodies (Fig. 4).
EL4-wt, vector-only–transfected EL4, and EL4–B7-2 cells
were unable to costimulate T cell proliferation (Fig. 4). The
EL4–B7-11B7-2 double transfectants were able to costim-
ulate T cell proliferation as well as the EL4–B7-1 cells. This
costimulation could be 60% blocked by the addition of
anti–B7-1 antibodies but more than 90% blocked with
anti–B7-2 antibody or CTLA4–Ig (Fig. 4). EL4–B7-11
B7-2 cells explanted after 20 d from tumors growing in
mice also retained the same costimulatory activity as the in
vitro-cultured EL4–B7-11B7-2 cells.
Figure 2. Tumorigenicity of
B7-transfected EL4 cells in vivo.
B7-transfected EL4 and EL4-wt
cells (2 3 106 cells/mouse) were
intradermally implanted into syn-
geneic C57BL/6 mice (A) or
C57BL/6 nu/nu mice (B) in
groups of five mice each. Tumor
growth was assessed every 2–3 d
by measuring in three perpendicu-
lar directions. The results are ex-
pressed as tumor volumes in mm3.
h, EL4-wt; e, EL4–B7-1; s,
EL4–B7-2; n, EL4–B7-11B7-2.
Table I. Tumor Growth of EL4-wt and Transfected Tumor Cells In Vivo
Incidence
of tumors
Incidence
of tumor
rejection
Tumor volume
on day 14
Maximal tumor
volume
Percent tumor-free on
day 20 day 30
mm3 6 SEM %
EL4-wt 20/20 0/20 1,092 6 584 4,208 6 883 0 0
EL4–B7-1 30/30 28/30  88 6 38  542 6 343 60 93
EL4–B7-2 23/23 1/23* 2,216 6 319‡ 3,873 6 396‡ 44
EL4–B7-11B7-2 30/30 5/30* 2,563 6 257‡ 3,707 6 343‡ 01 0
B7-transfected EL4 and EL4-wt cells (2 3 106 cells/mouse) were intradermally implanted into syngeneic C57BL/6 mice. The tumor volumes in
mm3 are the average tumor volumes from all mice in the experiment groups. Maximal tumor volume is calculated as average tumor volume in each
mouse on day of largest size.
*Significantly different from EL4–B7-1 group (P , 0.0001) by chi-square test.
‡Significantly different from EL4–B7-1 group (P , 0.0001) by unpaired t test.924 Interleukin 4–dependent Expression of Antitumor Immunity Induced by B7-2
Blocking B7-2 Molecules In Vivo Results in Inhibition of Tu-
mor Growth of the B7-11B7-2 Double-transfected EL4 Tu-
mors. To study whether the lack of antitumor immunity
induced by the double transfectant was due to a dominant
negative immunoregulation induced by the B7-2 mole-
cule, we implanted syngeneic C57BL/6 mice with the
double-transfected EL4–B7-11B7-2 cells and tested the
effect of blocking either B7-1 or B7-2 molecules with
monoclonal antibodies in vivo. Groups of mice were intra-
dermally implanted with EL4–B7-11B7-2 cells that were
premixed with excess (50 mg) anti–B7-1 or anti–B7-2 anti-
body to block the B7 molecules expressed on the cell sur-
face. The mice were further treated with i.p. injections of
150 mg of the anti-B7 antibody every other day for 20 d
after implantation of EL4 cells. Anti–B7-1 and anti–B7-2
antibodies are of the same isotype and thus control for each
other. A control group was injected i.p. every other day
with 200 ml PBS. In the anti–B7-1 antibody–treated group,
the EL4–B7-11B7-2 tumor grew as quickly as the PBS-
treated control group (Fig. 5 A), reaching experimental
limits between days 15 and 22. In other experiments, treat-
ment with anti–B7-1 antibody made the tumors grow
more quickly than the PBS treatment (data not shown). In
contrast, in the anti–B7-2 antibody–treated group, tumors
grew slowly or began to regress by day 15, indicating that
when the B7-2 molecule on the surface of the EL4 cell was
blocked, the signal provided by the B7-1 molecule became
dominant and induced regression. The experiment was dis-
continued at day 21, as the tumors in the PBS control and
anti–B7-1 antibody groups had reached experimental lim-
its. The in vivo effects of anti–B7-2 antibody in inducing
tumor regression could be due to its modification of the
immune response of the host and not just due to blocking
of B7-2 molecules on the surfaces of tumor cells. To ad-
dress this issue, we implanted EL4-wt cells into C57BL/6
host mice that were treated with anti–B7-1 antibodies,
anti–B7-2 antibodies, or a control Ig to determine if the
antibody treatments themselves were affecting the experi-
Figure 3. Stability of B7-2 expression on transfected cells in vitro and
in vivo. Tumors from mice implanted with EL4–B7-2 and EL4–B7-
11B7-2 cells were removed from the mice 20 d after implantation, made
into a single-cell suspension, and stained with FITC-conjugated anti–B7-1
mAb (16.10A1) and PE-conjugated anti–B7-2 mAb (GL1). The B7 ex-
pression was determined by flow cytometry for explanted EL4–B7-2 and
EL4–B7-11B7-2 tumor cells immediately after explantation and after
maintaining the explanted cells for 4 d in tissue culture. A total of 10,000
cells were analyzed by flow cytometry for each sample.
Figure 4. Costimulation of T cell proliferation in re-
sponse to submitogenic doses of anti-CD3 mAb by B7-
transfected EL4 and EL4-wt cells. T lymphocytes (5 3
104/well) were isolated from syngeneic C57BL/6 mice and
combined with EL4 stimulator cells (5 3 104/well) that
had been pretreated with 50 mg/ml mitomycin C over-
night. The cells were incubated for 48 h at 378C, pulsed
with 1 mCi/well 3H-TdR, incubated for an additional 14–
16 h, harvested, and the amount of TdR incorporation was
determined. The costimulatory effect of the B7 molecules
on T cell proliferation was blocked by the addition of 2 mg/
well of anti–B7-1 (1G10) mAb, anti–B7-2 (GL1) mAb, or
hCTLA4–Ig. The background proliferation of T cells
treated only with anti-CD3 antibody was ,2,000 cpm in
this assay. Mitomycin C–treated tumor cells, without T
cells, did not show any significant proliferation (100–300
cpm; data not shown). B7-112 exp. represents double-
transfected EL-4 cells obtained from in vivo–explanted tu-
mors.  Treatments: j, alone; hatched box, anti–B7-1; h,
anti–B7-2; dotted box, hCTLA4–Ig.925 Stremmel et al.
mental results. During the 20-d course of the experiment,
none of the antibodies had any significant effect on the
growth of the EL4-wt tumors in vivo (Fig. 5 B). Further-
more, in vitro treatment of EL4-wt, EL4–B7-1, EL4–B7-2,
and EL4–B7-11B7-2 cells with anti–B7-1 or anti–B7-2
antibodies did not inhibit or slow the in vitro growth rate
of the cells (data not shown).
Transfer of Immune Suppression by a T Cell Line and Spleen
Cells from EL4-B7–bearing Mice. To examine the role of
T cells in tumor rejection and immune suppression, T cell
lines from EL4–B7-1, EL4–B7-2, and EL4–B7-11B7-2
tumor–bearing mice were established. The T cell lines
were derived from spleens of mice bearing tumors im-
planted 10–12 d earlier. Because of the lack of costimula-
tory activity of EL4-wt and EL4–B7-2 cells, we have not
been successful in establishing long-term T cell lines against
these tumors. However, we were successful in establishing
long-term T cell lines against EL4–B7-1 and EL4–B7-1/2
double transfectant tumor cells. Three cell lines were estab-
lished from three mice bearing the EL4–B7-1 tumor, and
each of the three T cell lines were CD81 (.95%). All of
these T cells showed the same cytokine profile as demon-
strated for the T cell line No. 4 (Fig. 6 B), and all of them
lysed EL4-wt and EL4–B7-1 tumor cells in a CTL assay.
Five T cell lines were established from six mice bearing the
EL4–B7-11B7-2 tumor. Of these five lines following four
in vitro restimulations, four T cell lines were .93% CD41
T cells. The fifth cell line was 65% CD41 and 35% CD81.
This cell line was positive in a CTL assay for EL4–B7-1 and
the double-transfected tumor cells, but over time it lost the
CD81 T cells and CTL activity. Detailed analysis of two
prototypic T cell lines, No. 4 generated against the EL4–
B7-1 and No. 1 generated against EL4–B7-1/2 double
transfectants, is shown (Fig. 6). The No. 4 T cell line, gen-
erated against EL4–B7-1, was CD81 (.98%) and showed a
very strong and specific CTL activity for the different EL4
cells, including the EL4-wt cells, but did not lyse a control
tumor target R1.1–B7-1 (this cell line is also B7-1–trans-
fected; Fig. 6 A). After specific activation of T cell No. 4 with
EL4–B7-1, it produced high levels of IFN-g, low levels of
IL-10, and no IL-2, IL-4, or TNF-a (Fig. 6 B). This is
completely opposite to the response of T cell line No. 1,
which was derived from a mouse bearing the B7-1/2 dou-
ble-transfected tumor. This T cell No. 1 (.99% CD41)
showed no CTL activity at all (Fig. 6 A) and produced high
amounts of IL-4 and IL-10 but no IL-2, IFN-g, or TNF-a
in response to EL4–B7-11B7-2 (Fig. 6 B). Transfer of the
T cell line No. 1 i.v. into mice with a EL4–B7-1 tumor re-
sulted in tumor growth in 9/16 animals (Fig. 6 C). Fur-
thermore, the intravenous transfer of spleen cells from mice
with EL4–B7-2 tumors resulted in growth of EL4–B7-1
tumors (Fig. 6 C). Intravenous injection of PBS or normal
C57BL/6 spleen cells did not affect the tumor growth of
EL4–B7-1 cells. In contrast to the EL4–B7-1–expressing
tumor cells, which induce CTL responses, the data suggest
that expression of B7-2 on the EL4 cells results in the in-
duction of CD41 T cells that predominantly produce Th2
cytokines. To further confirm that it is CD41 cells that are
responsible for suppression of anti-tumor immunity, we
also tested the growth of EL4–B7-11B7-2 in B6 mice de-
pleted of CD41 cells. Groups of C57BL/6 mice were ei-
ther treated with control Ig or anti-CD4 mAb (GK1.5) and
then transplanted with EL4–B7-11B7-2 double transfec-
tants. The results showed that in the control Ig-treated
group, all mice developed tumors of large size; all mice had
to be killed because of the large tumor size. In contrast, in
the anti-CD4–treated group, average tumor size was much
smaller. In the latter group, 75% of mice were still alive on
day 24 and 25% of mice were actively rejecting tumors.
Figure 5. Effect of injection of anti-B7 antibodies on the tumorigenic-
ity of EL4–B7-11B7-2 or EL4-wt cells in vivo. Groups composed of five
syngeneic C57BL/6 mice each were intradermally implanted with 2 3
106 EL4–B7-11B7-2 cells (A) or EL4-wt cells (B) and injected i.p. with
150 mg/mouse of anti–B7-1 mAb (e), anti–B7-2 mAb (s), or PBS (h)
every other day. The cells had been premixed with 50 mg of anti–B7-1 or
anti–B7-2 mAbs before implantation. Treatment was stopped at day 20.
Tumor size was assessed every 2–3 d by measuring in three perpendicular
directions. The results are expressed as tumor volumes in mm3.926 Interleukin 4–dependent Expression of Antitumor Immunity Induced by B7-2
These data directly demonstrate that CD41 cells play an ac-
tive role in suppressing antitumor immunity.
EL4–B7-2 and B7-11B7-2 Cells Are Rejected in IL42/2
Mice. Previous studies have reported that B7-2 may pref-
erentially induce Th2 responses (25, 26). B7-2 expression
on EL4 cells probably results in the induction of IL-4–pro-
ducing Th2 or NK1.1 responses, which may in turn sup-
press antitumor responses. To further explore whether IL-4
and IL-10 were involved in the suppression of antitumor
immunity by EL4–B7-2 and EL4–B7-11B7-2 tumor cells,
we assessed the tumor growth of EL4-wt and transfectants
by intradermal implantation of 2 3 106 cells into syngeneic
IL-42/2, IL-102/2, and normal C57BL/6 mice.
EL4-wt and EL4–B7-1 tumor cells showed the same tu-
mor growth or tumor rejection in IL-4– or IL-10–deficient
mice as in normal C57BL/6 mice (Fig. 7, A and B). EL4-wt
cells produced visible tumors in the mice after 5–9 d (Fig. 7
A). B7-1–transfected EL4 cells were rejected in all three
groups by 13–20 d after implantation (Fig. 7 B). In con-
trast, EL4–B7-2–transfected tumor cells progressively grew
in normal C57BL/6 and IL-102/2 mice but were com-
pletely rejected in IL-42/2 C57BL/6 mice (Fig. 7 C). The
B7-11B7-2 double-transfected EL4 cells showed aggres-
sive tumor growth in the C57BL/6 control group, whereas
in the IL-42/2 and IL-102/2 mice, the EL4–B7-11B7-2
tumor cells were rejected (Fig. 7 D). These data demonstrate
that host-derived IL-4 and/or IL-10 plays a critical role in
abrogation of antitumor immunity induced by EL4–B7
transfectants.
Discussion
We have examined the costimulatory molecules B7-1
and B7-2 on EL4 thymoma cells for their ability to induce
antitumor immune responses. Our studies using B7-2–
transfected EL4 cells confirm the previously reported re-
sults that B7-1 and B7-2 expressed on EL4 tumor cells dif-
fer in the way they affect antitumor immunity and tumor
growth in vivo (22). Transfecting B7-2 into EL4 cells does
not induce antitumor immunity but results in more vigor-
Figure 6. In vitro and in vivo func-
tions of T cells derived from EL4–B7-1
or EL4–B7-11B7-2 tumor–bearing mice.
The long-term T cell lines were estab-
lished from spleens of mice which had the
EL4–B7-1 (T cell No. 4) or the double-
transfected tumor (T cell No. 1) for 12 d.
(A) Cytolytic responses of the two T cell
lines to different 51Cr-labeled targets at
different E/T ratios. The data are pre-
sented as % specific lysis. Similar results
were obtained in a total of six indepen-
dent experiments. (B) Cytokine produc-
tion of the T cell lines after 40 h of
activation with the corresponding EL4
transfectant. The cytokines were mea-
sured by an ELISA. Dotted bar, IL-4;
hatched bar, IL-10; j, IFN-g. One of
five independent experiments is shown.
(C) Effect of transfer of 4–5 3 106 cells
from T cell line No. 1 (generated from
EL4–B7-11B7-2–bearing mice) or spleen
cells from normal mice or mice bearing
EL4–B7-2 tumors into mice which were
implanted with EL4–B7-1 cells 24 h ear-
lier. Tumor size was assessed every 2–3 d
by measuring in three perpendicular directions. The results are expressed as mean tumor volumes in mm3. h, alone; e (left), T cell line No. 1; e
(right), spleen C57BL/6; s, spleen EL4–B7-2.927 Stremmel et al.
ous tumor growth. This is in sharp contrast to the complete
regression observed with the B7-1–transfected EL4 cells.
Interestingly, we observed in this study that expression of
B7-2 in B7-1–transfected EL4 cells does not result in tumor
regression but rather more aggressive growth of the tumor
cells. This suggests that the presence of B7-2 on the cell
surface was dominant, as it could suppress or negate the
ability of B7-1 to induce antitumor immunity and elimina-
tion of the tumor.
Although some investigators have reported that both B7-1
and B7-2 have equivalent costimulatory abilities (27), in-
creasing evidence suggests that the functional outcome of
B7-1– and B7-2–mediated signaling appears to have both
distinct and overlapping functions (26, 28, and 29). We and
others have recently demonstrated that expression of B7-1
on the surfaces of malignant tumor cells results in their re-
jection and can reduce tumor burden and eliminate estab-
lished metastases (17, 18). B7-2 has been transfected into a
number of different types of tumor cells with conflicting
results. Transfecting B7-2 into P815 mastocytoma cells (21)
or malignant melanoma tumors (30) resulted in tumor re-
gression. In contrast are the results obtained by Yang et al.
for the fibrosarcoma MCA 102 (21) and Gajewski (24),
who have reported that B7-1, but not B7-2, can efficiently
costimulate CD81 T lymphocytes. Leong et al. have found
that B7-1, but not B7-2, can induce immunity to murine-
malignant mesothelioma (31). Matulonis et al. have also re-
ported that B7-2 is less potent than B7-1 in inducing anti-
tumor immunity and tumor regression in myeloid cells
(23). Our results are consistent with the Leong et al. and
Matulonis et al. reports.
Why would the two B7 molecules behave differently,
even though they bind to the same receptors on the sur-
faces of T cells? There is some indirect evidence that sug-
gests that B7-1 is quantitatively superior to B7-2 in provid-
ing costimulation. The differences in affinity/avidity and
length of interaction (on/off rates) between B7 molecules
and the CD28/CTLA4 receptors may affect the intracellular
signaling events induced in T cells (29). Mechanisms which
could explain the B7-2 effect on the immune system include
the induction of anergy by preferentially engaging CTLA4,
activation of the fas/fas ligand apoptotic pathway, or the re-
cruitment of regulatory T cells producing inhibitory cyto-
kines. The induction of anergy through the CTLA4 pathway
does not appear to be an important mechanism of the ob-
served B7-2 effect, as in vivo blocking of CTLA4 using a
specific monoclonal antibody (whole or Fab) did not result
in the rejection of the EL4–B7-2 tumors (data not shown).
Th2 cells have been shown to be induced by B7-2 sig-
naling, leading to the downregulation of Th1 cells and
their associated cytokines. Kuchroo et al. (25) and Freeman
et al. (26) initially suggested that B7-1 and B7-2 may have
Figure 7. Tumor growth of
EL4-wt and B7-transfected EL4
cells in C57BL/6 (h) and IL-42/2
(s) and IL-102/2 (e) C57BL/6
mice. EL4-wt (A), B7-1–trans-
fected EL4 (B), EL4–B7-2 (C),
and EL4–B7-11B7-2 cells (D)
were intradermally implanted
into syngeneic C57BL/6 mice
and IL-4– and IL-10–deficient
C57BL/6 mice (2 3 106 cells/
mouse). Tumor growth was as-
sessed every 2–3 d by measuring
in three perpendicular direc-
tions. The results are expressed as
tumor volumes in mm3.928 Interleukin 4–dependent Expression of Antitumor Immunity Induced by B7-2
differential roles in T cell differentiation. Whereas B7-1
was suggested to induce Th1 differentiation, more compel-
ling evidence has been reported for the role of B7-2 in in-
ducing Th2 differentiation. Although they are controver-
sial, a number of studies have now confirmed this initial
observation (28, 29, and 33) and have also shown the im-
portance of B7-2 for IL-10 production (29). It is not yet
clear whether B7-2 expressed on the EL4 cells is inducing
differentiation of naive T cells into a Th2/Tc2 pathway or
whether it is expanding a memory Th2/Tc2 population. If
B7-2 expression does not directly result in Th2 differentia-
tion of the naive T cells, EL4–B7-2 cells may preferentially
expand a preexisting memory Th2/Tc2 cell population
that is cross-reactive with the EL4 cells. Although EL4 tu-
mor cells are MHC class II2, they induce CD41 T cells,
probably by indirect presentation in that the tumor antigen
of the EL4 cells is presented by host APCs. The rejection of
EL4–B7-2 and EL4–B7-11B7-2 tumor cells in IL-4–defi-
cient mice demonstrates the important role of this Th2 cy-
tokine in the regulation of an antitumor response in this
system. Thus, if B7-2–expressing EL4 cells predominantly
induced a Th2 response, these EL4-specific Th2 cells may
inhibit antitumor immune responses. The importance of
CD41 and not CD81 T cells for the immune-suppressive
effect of the EL4–B7-11B7-2 cells could be further dem-
onstrated in mice depleted of CD41 cells, as described in
the Results section: mice depleted of CD4 cells could reject
tumors or showed slower tumor growth when compared
with control Ig-treated mice. This data, together with the
results from the IL-4–deficient mice, which still have func-
tional CD4 compartments, supports the idea that Th2 cy-
tokines produced by CD4 cells induced by B7-2–bearing
tumor cells are responsible for suppression of antitumor im-
munity in vivo. A few earlier studies have shown that pref-
erential induction of Th2 responses may suppress specific
antitumor immunity. Ghosh et al. have suggested that Th2
cells dominate in progressive tumor–bearing animals, re-
ducing the number of Th1 cells and their associated cyto-
kines and thus allowing the tumor to grow in the host (34).
IL-10 has been implicated in reducing the ability of CD81
T cells (CTLs) to eliminate tumors in vivo (35, 36). The in
vivo data for IL-42/2 C57BL/6 mice further supports the
hypothesis that B7-2 may be delivering a dominant costim-
ulatory signal which induces IL-4, producing Th2-like re-
sponses. It would then follow that IL-4 and IL-10 would
be produced by these cells, leading to inhibition of Th1
cells and CTL activity and favoring tumor growth. Our
data further supports this hypothesis, in that transfer of T
cells from B7-11B7-2 tumor–bearing mice inhibited anti-
tumor immunity in mice challenged with EL4–B7-1 cells.
This may be part of the explanation for the B7-2 effect we
have observed.
Functional differences in the effect of B7-2 expression
on different cell types might be due to quantitative differ-
ences in surface expression, cell-specific posttranslational
modifications in the B7-2 molecule, different isoforms of
B7-2 used for transfection, or mutation in the cDNA. The
same murine B7-2 cDNA preparation was transfected into
cells of different tissue types such as CHO, 3T3, and
BW1100 cells. We have found that only the EL4 cells ex-
pressing B7-2 failed to costimulate, eliminating the possi-
bility that the cDNAs are different (22). Freshly isolated
splenic T cells from a number of strains of mice were also
examined and found to be unable to costimulate T cells in
in vitro allo-MLRs, although they all expressed low levels
of B7-2 as determined by flow cytometry. These two
pieces of data argue against there being a mutation in the
B7-2 cDNA used for transfection. Quantitative differences
in B7-2 expression on the surfaces of the cells is also not a
likely explanation for the observed inability of EL4–B7-2
and EL4–B7-11B7-2 cells to induce antitumor immunity.
We tested low and high B7-2–expressing EL4 cells, and all
showed similar tumor growth in vivo (data not shown).
Also, in the case of EL-4–B7-11B7-2 double transfectants,
there is high expression of both costimulatory molecules
yet tumors grow progressively in the host. Quantitatively
lower expression of B7 may not, therefore, be responsible
for the observed effect. Furthermore, overexpression of
B7-2 on EL-4 cells does not lead to induction of antitumor
immunity, suggesting that B7-2 expressed on EL-4 or
other T cells may be qualitatively different. In support of
this hypothesis, Höllsberg et al. (37) have reported that hu-
man T cells express a hypoglycosylated form of B7-2 that
exhibits a reduced ability to bind CD28 and does not co-
stimulate T cell proliferation. This also indicates that B7-2
expressed on the surfaces of T cells may be qualitatively dif-
ferent. It is possible that B7-2 exists in different forms in
various cell types and that posttranslational modifications
can affect the binding and functions of the B7-2 molecule.
The conflicting reports concerning B7-2 effects on the
antitumor response may be due in part to sequence differ-
ences in the B7-2 construct used for transfection. Compar-
ison of the published sequences of B7-2 by Freeman et al.
(12) and Azuma et al. (5) indicates the presence of six addi-
tional residues at the amino terminus of the B7-2 sequence
isolated by Freeman et al. It is possible that these six addi-
tional amino acids, which are encoded by a separate exon
(38), can affect the function of the B7-2 molecule or shunt
it into different intracellular processing pathways within the
cell. This could result in conformational changes in protein
folding or posttranslational modifications (e.g., glycosyla-
tion), leading to alterations in the function of the B7-2
molecule in some cell types, such as tumors of T cell origin.
In summary, data presented here demonstrates that,
whereas B7-1 and B7-2 enhance immune responses by
providing a potent costimulatory signal to the T cell, B7-2
may serve to inhibit immune responses under some cir-
cumstances. The Th2 cytokine, IL-4 appears to play an im-
portant role in abrogating the antitumor response induced
by the B7-2 molecule on EL4 cells. B7 molecules may thus
have evolved with the capability to both enhance and reg-
ulate the immune response, depending on which receptor
they engage (CD28 vs. CTLA4) and the cell type in which
they are expressed (professional APC vs. T cell).929 Stremmel et al.
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